Mesoblast Limited (MSB.AX)
| Previous close | 0.9400 |
| Open | 0.9400 |
| Bid | 0.9250 x 1092600 |
| Ask | 0.9450 x 5097500 |
| Day's range | 0.9250 - 0.9700 |
| 52-week range | 0.6100 - 1.3300 |
| Volume | |
| Avg. volume | 1,693,742 |
| Market cap | 681.335M |
| Beta (5Y monthly) | 2.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1900 |
| Earnings date | 27 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.01 |
- GlobeNewswire
FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing
Biologics License Application (BLA) Resubmission for Pediatric Acute Graft-Versus-Host Disease (SR-aGVHD) Currently Being Reviewed PDUFA Goal Date August 2, 2023 If Approved, Remestemcel-L will be the First Allogeneic “Off-the-Shelf” Cellular Medicine in the US, and the First Therapy for Children Under 12 Years Old with SR-aGVHD NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today an
- Zacks
Mesoblast's (MESO) GVHD Drug BLA Gets FDA Priority Tag, Stock Up
Mesoblast (MESO) announces the FDA acceptance for review of the resubmitted biological license application for remestemcel-L for the treatment of children under 12 with steroid-refractory acute graft versus host disease. Stock gains on Wednesday, following the news.
- GlobeNewswire
FDA Accepts Mesoblast’s Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023
If Approved, Remestemcel-L will be the First Allogeneic “Off-the-Shelf” Cellular Medicine in the US, and the First Therapy for Children Under 12 Years Old with SR-aGVHD.NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration’s (FDA) Office of Therapeutic Products (OTP) has accepted the Company’s Biologics License Application
